COMMUNIQUÉS West-GlobeNewswire

AnswersNow Completes $40M Series B to Expand BCBA-Driven, AI-Enabled Autism Therapy
21/01/2026
RICHMOND, Va., Jan. 21, 2026 (GLOBE NEWSWIRE) -- AnswersNow , the leader in virtual Applied Behavioral Analysis (ABA) therapy, today announced that it has raised $40 million in Series B funding led by HealthQuest [...]
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
21/01/2026
Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestones Offer represents an approximate 85% premium over the most recent [...]
Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer
21/01/2026
Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA ® while at Regeneron Most recently served as Chief Marketing Officer, Global [...]
Skye Bioscience to Present Poster at Keystone Obesity Conference
21/01/2026
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health [...]
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
21/01/2026
REDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it will present a [...]
FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study
21/01/2026
HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Hopstem Biotechnology Inc. (hereinafter referred to as "Hopstem"), a company dedicated to the development of induced pluripotent stem cell (iPSC)-derived allogeneic neural cell [...]
Crucial Innovations Corp. Launches 4TP, a New Patient-Focused Brand of Cannabis-Based Products for Medicinal Use
21/01/2026
4TP (“For The People”) introduces carefully cultivated CBPMs supported by transparent education and a commitment to consistent high-quality medicine LONDON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Crucial Innovations Corp. ( [...]
Angelini Pharma Announces Appointment of Sergio Marullo di Condojanni as New CEO
21/01/2026
CEO of family company Angelini Industries will also lead the pharmaceutical company from today, bringing strong leadership experience and strategic vision ROME, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Angelini Pharma, part of [...]
AMSilk’s bioengineered silk protein yarns debut in Balenciaga Spring 2026 Collection
21/01/2026
First commercially available products using AMSilk’s biotech silk protein yarns Demonstrating a scalable, low impact alternative to conventional silk within luxury fashion Designed for resilient, transparent and [...]
Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering
21/01/2026
MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“ Anteris ” or the “ Company ”) (NASDAQ: AVR , ASX: AVR), a global structural heart company committed to [...]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 15, 2026 it granted stock options to purchase an aggregate of 29,416 shares of [...]
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
20/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public [...]
Erasca Announces Proposed Public Offering of $150 Million of Common Stock
20/01/2026
SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/ [...]
BioAge Announces Proposed Public Offering
20/01/2026
EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic [...]
Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic
20/01/2026
MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“ Anteris ” or the “ Company ”) (NASDAQ: AVR , ASX: AVR), a global structural heart company committed to [...]
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025
20/01/2026
Vancouver, Canada, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel [...]
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders
20/01/2026
BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight [...]
Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds
20/01/2026
LITTLETON, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on sleep related breathing [...]
Protext Mobility, Inc. (OTC: TXTM) is thrilled to share a transformative update, advancing uplisting readiness with a preliminary Deloitte engagement
20/01/2026
FORT LAUDERDALE, Fla., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Protext Mobility, Inc. (OTC: TXTM) (“Protext” “TXTM” or the “Company”) is thrilled to share a transformative update that underscores its strategic execution, [...]

Pages